Why is Concord Biotech Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate -0.48% of over the last 5 years
2
Negative results in Sep 25
- PBT LESS OI(Q) At Rs 72.33 cr has Fallen at -32.1% (vs previous 4Q average)
- PAT(Q) At Rs 63.58 cr has Fallen at -28.6% (vs previous 4Q average)
- OPERATING CF(Y) Lowest at Rs 244.52 Cr
3
With ROE of 17.7, it has a Very Expensive valuation with a 8 Price to Book Value
- The stock is trading at a fair value compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -35.20%, its profits have fallen by -1.2%
4
Below par performance in long term as well as near term
- Along with generating -35.20% returns in the last 1 year, the stock has also underperformed BSE500 in the last 3 years, 1 year and 3 months
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Concord Biotech for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Concord Biotech
-23.78%
-0.80
43.99%
Sensex
-2.0%
0.44
11.83%
Quality key factors
Factor
Value
Sales Growth (5y)
6.44%
EBIT Growth (5y)
-4.46%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.63
Tax Ratio
25.31%
Dividend Payout Ratio
24.63%
Pledged Shares
0
Institutional Holding
18.35%
ROCE (avg)
26.62%
ROE (avg)
17.36%
Valuation Key Factors 
Factor
Value
P/E Ratio
40
Industry P/E
40
Price to Book Value
5.54
EV to EBIT
33.57
EV to EBITDA
27.36
EV to Capital Employed
6.78
EV to Sales
9.45
PEG Ratio
NA
Dividend Yield
0.69%
ROCE (Latest)
20.19%
ROE (Latest)
13.72%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Technical Movement
5What is working for the Company
NET SALES(Latest six months)
At Rs 566.56 cr has Grown at 25.61%
PAT(Latest six months)
At Rs 129.18 cr has Grown at 20.01%
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Concord Biotech
Net Sales - Latest six months
At Rs 566.56 cr has Grown at 25.61%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Profit After Tax (PAT) - Latest six months
At Rs 129.18 cr has Grown at 20.01%
Year on Year (YoY)MOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)